Opioid REMS Hearing Features Top-Level FDA Team – But No Manufacturers
Executive Summary
FDA’s most recent public meeting to explore better approaches to managing prescription opioids marked the public debut of its new Opioid Steering Committee. The issue has top management attention at FDA – but the hearing didn’t include any industry speakers.
You may also be interested in...
State Opioid Prescribing Databases Can Handle US FDA's Needs, Officials Say
Pharma firms might avoid paying for national opioid prescription monitoring database because state systems already talk to each other, although current operations still need some upgrades.
Opioid Policy At US FDA To Become 'More Forceful,' Gottlieb Says
Whether to require physician education, when to limit the doses prescribed to patients, and how to weigh societal abuse potential in approvals are the initial questions for the Opioid Policy Steering Committee.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.